Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.57 USD
Change Today +0.07 / 4.67%
Volume 606.1K
BSPM On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

biostar pharmaceuticals inc (BSPM) Snapshot

Open
$1.52
Previous Close
$1.50
Day High
$1.58
Day Low
$1.41
52 Week High
08/21/14 - $2.27
52 Week Low
01/30/15 - $0.91
Market Cap
24.3M
Average Volume 10 Days
487.5K
EPS TTM
$0.43
Shares Outstanding
15.5M
EX-Date
--
P/E TM
3.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSTAR PHARMACEUTICALS INC (BSPM)

Related News

No related news articles were found.

biostar pharmaceuticals inc (BSPM) Related Businessweek News

No Related Businessweek News Found

biostar pharmaceuticals inc (BSPM) Details

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People’s Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for the treatment of chronic hepatitis B. Its current product line also includes 5 other OTC products, 10 prescription-based pharmaceuticals, 6 nutriceuticals or health products, and 1 medical device. The company’s OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat pain, headache, and fever; and Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for the treatment of pain and other symptoms associated with menstruation. Its prescription pharmaceutical products include Danshen granule for the treatment of coronary heart disease, myocarditis, and angina pectoris; and Taohuasan pediatric medicine for the treatment of bronchial congestion and coughs in children. In addition, the company manufactures hernia belt, a medical device used for the relief of hernia. Further, it provides nutrient and OTC products, which comprise Tangning capsule for the treatment of diabetes; Yizi capsule for fertility; Shengjing capsule for kidney; and Aoxing ointment to treat psoriasis, vitiligo, and various dermatitis. Additionally, the company operates zggbyy.com, a Website that serves as Internet-based China Hepatitis Internet hospital, which provides HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through 68 distributors and a network of approximately 226 dedicated sales people in approximately 27 provinces. The company is headquartered in Xianyang, the People’s Republic of China.

biostar pharmaceuticals inc (BSPM) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $17.4K
Interim Chief Financial Officer and Director
Total Annual Compensation: $11.0K
Chief Operating Officer
Total Annual Compensation: $6.6K
Compensation as of Fiscal Year 2013.

biostar pharmaceuticals inc (BSPM) Key Developments

Biostar Pharmaceuticals Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Biostar Pharmaceuticals announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the year, sales were $61,416,587, loss from operations was $1,312,695, income before income taxes was $1,534,631 and net income was $4,848,212 or $0.33 per diluted share against sales of $52,729,054, income from operations of $508,221, income before income taxes of $2,656,026 and net income of $809,046 or $0.07 per diluted share a year ago. Net cash provided by operating activities was $3,310,618 against $8,909,113 a year ago. Purchase of property, plant and equipment was $2,869,204 against $982,012 a year ago. Net sales in the fourth quarter of 2014 was $14.4 million as compared to $11.0 million during the same period in 2013, representing a $3.4 million, or 31.0% increase. Net income for the quarter was $2.7 million.

Biostar Pharmaceuticals Mulls Acquisitions

Biostar Pharmaceuticals, Inc. (NasdaqCM:BSPM) is seeking acquisitions. Ronghua Wang, Chairman and Chief Executive Officer Of Biostar Pharmaceuticals, Inc., said “The Company also believes that economies of scale is vital to continue to improve its bottom line accordingly, when the right opportunity presents itself, the Company will consider acquiring competitors to ramp up its production.”

Biostar Pharmaceuticals, Inc. announced delayed annual 10-K filing

On 04/01/2015, Biostar Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSPM:US $1.57 USD +0.07

BSPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSPM.
View Industry Companies
 

Industry Analysis

BSPM

Industry Average

Valuation BSPM Industry Range
Price/Earnings 4.7x
Price/Sales 0.4x
Price/Book 0.3x
Price/Cash Flow 5.0x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSTAR PHARMACEUTICALS INC, please visit www.biostarpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.